Response Genetics Inc. announced it has launched a new and innovative Non-Small Cell Lung Cancer Profile that merges rapid turnaround on National Comprehensive Cancer Network (NCCN) guideline markers with next-generation sequencing (NGS). This new reflex, or sequential, testing program offers oncologists and pathologists a cost-effective way to utilize comprehensive cancer testing, including NGS, as a reflex-testing option for those patients who test negative for EGFR, ALK and ROS1, the biomarkers recommended by the NCCN.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.000001 USD | -.--% |
|
-.--% | -.--% |
2016 | Response Genetics, Inc Bankruptcy Case Dismissed | CI |
2016 | Motion for Case Dismissal Filed for Response Genetics, Inc | CI |
1st Jan change | Capi. | |
---|---|---|
-.--% | 38 | |
+34.14% | 5.11TCr | |
-6.54% | 3.94TCr | |
+34.92% | 3.85TCr | |
+12.62% | 2.64TCr | |
-12.11% | 2.62TCr | |
-13.43% | 2.1TCr | |
+43.73% | 1.4TCr | |
+31.81% | 1.25TCr | |
-4.54% | 1.16TCr |
- Stock Market
- Equities
- RGDXQ Stock
- News Response Genetics, Inc
- Response Genetics, Inc. Launches New and Innovative Non-Small Cell Lung Cancer Profile